我院發(fā)表新冠病毒藥物研究綜述文章：《COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine》
???近日，國際學(xué)術(shù)期刊《Virologica--Sinica》在線發(fā)表了我院張其威教授研究組題為"COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine"的文章，本文介紹了全世界有發(fā)展前景的新冠病毒治療藥物，包括現(xiàn)存的抗病毒藥物的老藥新用、基于網(wǎng)絡(luò)的藥理學(xué)研究、抗體藥物和傳統(tǒng)中藥研發(fā)。部分藥物已進(jìn)入最后一個臨床試驗階段或已批準(zhǔn)用于臨床新冠病毒治療。該綜述文章對比分析新冠病毒各種治療藥物實(shí)驗室和臨床治療效果，有助于促進(jìn)新冠治療藥物的研發(fā)和改進(jìn)，并為臨床治療和應(yīng)用提供重要參考。
摘要：世界衛(wèi)生組織（WHO）宣布2019年底出現(xiàn)的由新型冠狀病毒SARS-CoV-2引起的冠狀病毒疾?。–OVID-19）是第一個冠狀病毒全球大流行。目前世界上還未出現(xiàn)有效的抗SARS-CoV-2藥物獲批用于治療COVID-19患者，因此迫切需要提供多種治療選擇應(yīng)對新冠病毒疾病暴發(fā)。為促進(jìn)新冠肺病毒治療藥物的更好和更快發(fā)展，并為臨床治療提供參考意見，我們在此介紹一些有發(fā)展前景的治療藥物，包括現(xiàn)存的抗病毒藥物的老藥新用、基于網(wǎng)絡(luò)的藥理學(xué)研究、抗體開發(fā)和中藥發(fā)展。其中部分藥物已進(jìn)入最后一個臨床試驗階段。
Abstract: The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no effective anti-SARS-CoV-2 drug approved worldwide for treatment of patients with COVID-19. Therapeutic options in response to the COVID-19 outbreak are urgently needed. To facilitate the better and faster development of therapeutic COVID-19 drugs, we present an overview of the global promising therapeutic drugs, including repurposing existing antiviral agents, network-based pharmacology research, antibody development and traditional Chinese medicine. Among all these drugs, we focus on the most promising drugs (such as favipiravir, tocilizumab, SARS-CoV-2 convalescent plasma, hydroxychloroquine, Lianhua Qingwen, interferon beta-1a, remdesivir, etc.) that have or will enter the final stage of human testing—phase III–IV clinical trials.
參考文獻(xiàn)：
? ? Wenyi Guan, Wendong Lan, Jing Zhang, Shan Zhao, Junxian Ou, Xiaowei Wu, Yuqian Yan, Jianguo Wu and Qiwei Zhang. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. Virologica Sinica.? 2020: 10.1007/s12250-12020-00297-12250.
版權(quán)與免責(zé)聲明：本網(wǎng)頁的內(nèi)容由收集互聯(lián)網(wǎng)上公開發(fā)布的信息整理獲得。目的在于傳遞信息及分享，并不意味著贊同其觀點(diǎn)或證實(shí)其真實(shí)性，也不構(gòu)成其他建議。僅提供交流平臺，不為其版權(quán)負(fù)責(zé)。如涉及侵權(quán)，請聯(lián)系我們及時修改或刪除。郵箱：sales@allpeptide.com